Evidence map›Paper›PMID 29620581›Full record

ArticleInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2019

Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case.

Mahkam Tavallaee, David F Steiner, James L Zehnder, Ann K Folkins, Amer K Karam

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mahkam TavallaeeDepartment of Pathology (M.T., D.F.S., J.L.Z., A.K.F.) Department of Obstetrics and Gynecology (A.K.K.) Department of Medicine (J.L.Z.), Stanford University School of Medicine, Stanford Department of Obstetrics and Gynecology, UCSF Fresno, Fresno (M.T.), California.
David F Steiner
James L Zehnder
Ann K Folkins
Amer K Karam
California State University, Fresno · USStanford University · US

Funding

TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos · 1989 to 2026
$73.3M
NCI NIH HHS P01 CA049605
6 · The paper itself

Abstract

Low-grade serous carcinomas only rarely coexist with or progress to high-grade tumors. We present a case of low-grade serous carcinoma with transformation to carcinosarcoma on recurrence in the lymph node. Identical BRAF V600E and telomerase reverse transcriptase promoter mutations were identified in both the original and recurrent tumor. Given that telomerase reverse transcriptase promotor mutations are thought to play a role in progression of other tumor types, the function of telomerase reverse transcriptase mutations in BRAF mutated low-grade serous carcinoma deserves investigation.

Indexed as

AgedCarcinosarcomaDisease ProgressionFemaleHumansLymph NodesMutationOvarian NeoplasmsOvaryPromoter Regions, GeneticProto-Oncogene Proteins B-rafTelomeraseBRAF protein, humanProto-Oncogene Proteins B-rafTelomeraseTERT protein, human

Identifiers

PMID29620581
PMCPMC6170737
OpenAlexW2795901700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.